Condition

Anemia, Sickle Cell (1)

Gamma Delta Hepatosplenic T-Cell Lymphoma (1)

NK T-Cell Lymphoma (1)

Subcutaneous Panniculitis-Like T-Cell Lymphoma (1)

T-Cell Peripheral Lymphoma (1)

Type 1 Diabetes Mellitus (1)

Overall Status

Completed (1)

Not yet recruiting (1)

Recruiting (1)

Phase

phase 1/phase 2 (2)

phase 1 (1)

Sponsor

Markus Mapara (1)

National Cancer Institute (NCI) (1)

National Institute of Allergy and Infectious Diseases (NIAID) (1)

Collaborator

ITB-Med LLC (1)

Study Documents

Intervention Type

drug (3)

biological (1)

procedure (1)

Funder Type

NIH (2)

Other (1)

Study Type

Interventional (3)

siplizumab

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Anemia, Sickle Cell Trial in New York (Siplizumab, Exchange Transfusion, Total Body Irradiation)

Recruiting

Anemia, Sickle Cell

Siplizumab
+7 more

New York, New York

Columbia University Irving Medical Center

Oct 9, 2023

Type 1 Diabetes Trial in United States (Siplizumab)

Not yet recruiting

Type 1 Diabetes Mellitus

Siplizumab

Birmingham, Alabama
+19 more

Jan 25, 2023

T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma Trial run

Completed

Has Results

T-Cell Peripheral Lymphoma
+3 more

Rituximab
+6 more

Bethesda, Maryland

National Institutes of Health Clinical Center, 9000 Rockville Pi

Oct 28, 2021